New anti-objective injection: Loss of weight by 25.4%, what did scientists discover?

New anti-objective injection: Loss of weight by 25.4%, what did scientists discover?

New anti-objective injection: Loss of weight by 25.4%, what did scientists discover?

Recent results show that reaction during the first few weeks may be related to the success of treatment

An experimental drug against obesity has recorded average weight loss of 25.4% to a group of participants in a clinical study, while new results show that response in the first eight weeks can be linked to the success of treatment in the longer term.

3M Express sponsor

Data released November 15th 2026 of the Novo Nordisk pharmaceutical companyDuring the ObbetyWeek 2026 science conference, held in Washington.

The center of attention is CagriSema, an experimental combination of two active substances, cagrilintide and semagluthide, which operate through various hormonal mechanisms to influence appetite and sense of satisfaction.

But the most interesting innovation is not limited to lost pounds. Researchers have found that participants do not respond to treatment in the same way and that changes may be observed in the first few weeks.

What did scientists discover after eight weeks?

By Results released by Novo Nordisk on November 15thA new phase three study analysis REDEFINS 1 showed that 67.8% of participants who received CarySema had lost at least 5% of their body weight within the first eight weeks.

These participants were classified as persons with early responses to treatment.

After 68 weeks, the average weight loss in this group reached the 25.4%, while the participants who reacted the slower was 17.8%.

To make it easier, a person who begins his 100 – pound [100 kg] treatment – if he reaches a loss of 25.4% – ends up at about 74.6 kg].

However, this percentage is not the average result of all people treated by CarySema, but only of the group that had reacted earlier, the Telegraph broadcast.

Another result drew attention

Of the participants who reacted early, 73.3% managed to lose at least 20% of their initial weight until 68th week.

In the group that reacted slower, this weight loss rate reached 37.2% of participants.

This shows an important link between the initial pace of weakness and subsequent results.

However, researchers point out that the analysis is exploratory. It has been conducted after completing the main study and does not prove that the answer during the first eight weeks can certainly predict the patient’s individual outcome.

Not just weakness: Improvements in Daily Life

Another analysis presented during ObetityWeek 2026 has praised the influence of CarySema on physical function and psychological well-being.

By official study data R EDEFIN 1, 73.1% of the participants who received CapriSema reported significant improvements in physical functioning, compared to 49.1% in the placebo group.

The improvements involved the ability to carry out day – to – day activities and the physical limitations associated with weight.

Psychologically, significant results were also recorded: 69% of participants receiving CagriSema reported significant improvements, against 42.1% of those who received placebo.

This data suggests that possible benefits from treatment of obesity can go beyond bodily weight change.

Does this mean that the drug works in all people alike?

No. It is the difference between participants that constitutes one of the most important messages in the new analysis.

A slower reaction does not necessarily mean a lack of effect. Even the group that failed to lose 5% of its weight during the first eight weeks recorded significant losses after 68 weeks.

Also, CagriSema remains experimental treatment and has not yet been approved for ordinary use. Security, side effects and long-term benefits continue to be part of the clinical evaluation.

What difference does it make after the final results?

The discovery presented on November 15th opens an interesting direction in dealing with obesity: the best sense of how patients react to drugs and identify factors related to the success of treatment.

The new data, however, is not yet the basis for changing clinical decisions solely on weight loss in the first few weeks.

The results of ObbetyWeek 2026 show that science is progressing toward increasingly individualized treatments, with the importance not only of the patient’s loss of weight but also of improving his health and quality of life. /Telegraphy/

Read more

How can we wake up happier in the morning?

How can we wake up happier in the morning?

The patient who died of breast cancer, the letter Minister Vitita for her lack of therapy: This is the hope of my life

The patient who died of breast cancer, the letter Minister Vitita for her lack of therapy: This is the hope of my life

Letter to Minister Arben Vitita of the patient who died of cancer: Please take measures to ensure therapy!

Letter to Minister Arben Vitita of the patient who died of cancer: Please take measures to ensure therapy!